C12Y 302/01045
Glucosylceramidase , i.e. beta-glucocerebrosidase
Official title: Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
C12Y302/01045 (Glucosylceramidase , i.e. beta-glucocerebrosidase) appears on 164 US grants and 285 published applications in this corpus.
Search patents in C12Y- Granted patents
- 164
- Published applications
- 285
- Assignees
- 112
- Inventors
- 480
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 1 | 2 |
| 2002 | 5 | 4 |
| 2003 | 2 | 7 |
| 2004 | 1 | 11 |
| 2005 | 4 | 6 |
| 2006 | 2 | 3 |
| 2007 | 1 | 5 |
| 2008 | 0 | 1 |
| 2009 | 2 | 5 |
| 2010 | 3 | 7 |
| 2011 | 4 | 10 |
| 2012 | 2 | 7 |
| 2013 | 6 | 23 |
| 2014 | 7 | 12 |
| 2015 | 14 | 14 |
| 2016 | 10 | 12 |
| 2017 | 12 | 12 |
| 2018 | 6 | 12 |
| 2019 | 10 | 10 |
| 2020 | 8 | 22 |
| 2021 | 10 | 16 |
| 2022 | 7 | 15 |
| 2023 | 9 | 22 |
| 2024 | 13 | 10 |
| 2025 | 7 | 23 |
| 2026 | 5 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating symptoms and disorders associated with lysosomal storage diseases15 Sep 2026US 12,734,160 B2Genzyme Corporation
- Recombinant adeno-associated virus compositions and methods for producing same8 Sep 2026US 12,729,385 B2Prevail Therapeutics, Inc.
- Recombinant AAV vectors for treating neurodegenerative disorders21 Apr 2026US 12,605,467 B2Shanghai Vitalgen Biopharma Co., Ltd.
- Gene therapies for lysosomal disorders10 Mar 2026US 12,570,963 B2Prevail Therapeutics, Inc.
- Gene therapies for lysosomal disorders10 Mar 2026US 12,571,002 B2Prevail Therapeutics, Inc.
- Compositions and methods for the treatment of disorders related to glucosylceramidase beta 1 deficiency17 Sep 2026US 2026/0275314 A1Voyager Therapeutics, Inc.
- Gene therapies for lysosomal disorders27 Aug 2026US 2026/0250715 A1Prevail Therapeutics, Inc.
- Anti-transferrin receptor antibodies and uses thereof20 Aug 2026US 2026/0242498 A1Biogen MA Inc.
- Oligonucleotides capable of upregulating glucocerebrosidase expression20 Aug 2026US 2026/0242796 A1Hoffmann-La Roche Inc.
- Engineered glucocerebrosidase variants13 Aug 2026US 2026/0234590 A1Embold Therapeutics, Inc.
Most cited
By later US patents
- Eukaryotic layered vector initiation systems204US 5,814,482 A1998
- Alphavirus vector constructs167US 5,843,723 AChiron Corporation · 1998
- Alphavirus structural protein expression cassettes152US 5,789,245 AChiron Corporation · 1998
- Eukaryotic layered vector initiation systems126US 6,015,686 AChiron Viagene, Inc. · 2000
- Production of lysosomal enzymes in plant-based expression systems117US 5,929,304 ACroptech Development Corporation · 1999